drugset / Trial / NCT01031199

Evaluation of the Positron Emission Tomography (PET) Tracer ZK 6032924 in Patients With Multiple Sclerosis Compared to Healthy Volunteers

NCT01031199 ↗

Phase 1 Completed 16 enrolled Bayer
Non-randomizedParallel-groupOpen-labelDiagnostic

Summary

PET (positron emission tomography) imaging with BAY85-8101 for investigation in patients with Multiple Sclerosis compared to healthy volunteers

Timeline

Start
2009-01
Primary completion
2009-12
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Subject F-18 FEDAA1106 Diagnostic / imaging agent 140 mbq Intravenous

Indications